James Quigley
Stock Analyst at Morgan Stanley
(0.91)
# 3,783
Out of 4,911 analysts
22
Total ratings
66.67%
Success rate
-15.5%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Upgrades: Overweight | $49 → $79 | $45.74 | +72.72% | 6 | Jun 3, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $50.37 | +29.05% | 1 | Mar 21, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | $119 → $121 | $117.70 | +2.80% | 1 | Sep 5, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $10.10 | +3.96% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $32.65 | +22.51% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $4.26 | +275.59% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Jun 3, 2025
Upgrades: Overweight
Price Target: $49 → $79
Current: $45.74
Upside: +72.72%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $50.37
Upside: +29.05%
Novartis AG
Sep 5, 2024
Downgrades: Neutral
Price Target: $119 → $121
Current: $117.70
Upside: +2.80%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $10.10
Upside: +3.96%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $32.65
Upside: +22.51%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $4.26
Upside: +275.59%